Rapport Therapeutics, Inc. (RAPP)
$48.81-$2.06 (-4.05%) Today
Abraham Ceesay - Officer
Krishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerRapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 20 | 149,624 | $7.09M |
| Grant or award | 8 | 121,600 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
61 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Paul M. Silva | Grant or award | Stock Option (Right to Buy) | 29,756 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 61 RAPP filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| KRISHNASWAMY YELESWARAM | Officer | 37,000 | $1.83M | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 11,472 | $553K | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 2,092 | $103K | View on EDGAR |
Rapport Therapeutics, Inc. (RAPP) had 16 insider filings in the last 90 days, with the most recent on 2026-08-26. The full record for RAPP runs to 61 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RAPP were filed in the last 90 days. 4 purchases are on record for this company.
20 insider sales of RAPP were filed in the last 90 days, totaling $7.09M.
This page tracks RAPP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RAPP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
